These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 34602251)

  • 1. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.
    Kanwal F; Shubrook JH; Adams LA; Pfotenhauer K; Wai-Sun Wong V; Wright E; Abdelmalek MF; Harrison SA; Loomba R; Mantzoros CS; Bugianesi E; Eckel RH; Kaplan LM; El-Serag HB; Cusi K
    Gastroenterology; 2021 Nov; 161(5):1657-1669. PubMed ID: 34602251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
    Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
    Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
    Long MT; Noureddin M; Lim JK
    Gastroenterology; 2022 Sep; 163(3):764-774.e1. PubMed ID: 35842345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparing for the NASH Epidemic: A Call to Action.
    Kanwal F; Shubrook JH; Younossi Z; Natarajan Y; Bugianesi E; Rinella ME; Harrison SA; Mantzoros C; Pfotenhauer K; Klein S; Eckel RH; Kruger D; El-Serag H; Cusi K
    Gastroenterology; 2021 Sep; 161(3):1030-1042.e8. PubMed ID: 34416976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.
    Arab JP; Candia R; Zapata R; Muñoz C; Arancibia JP; Poniachik J; Soza A; Fuster F; Brahm J; Sanhueza E; Contreras J; Cuellar MC; Arrese M; Riquelme A
    World J Gastroenterol; 2014 Sep; 20(34):12182-201. PubMed ID: 25232252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.
    Shaheen AA; Riazi K; Medellin A; Bhayana D; Kaplan GG; Jiang J; Park R; Schaufert W; Burak KW; Sargious M; Swain MG
    CMAJ Open; 2020; 8(2):E370-E376. PubMed ID: 32414883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    Shelley K; Articolo A; Luthra R; Charlton M
    BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options.
    Milic S; Mikolasevic I; Krznaric-Zrnic I; Stanic M; Poropat G; Stimac D; Vlahovic-Palcevski V; Orlic L
    Drug Des Devel Ther; 2015; 9():4835-45. PubMed ID: 26316717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
    Tokushige K; Ikejima K; Ono M; Eguchi Y; Kamada Y; Itoh Y; Akuta N; Yoneda M; Iwasa M; Yoneda M; Otsuka M; Tamaki N; Kogiso T; Miwa H; Chayama K; Enomoto N; Shimosegawa T; Takehara T; Koike K
    J Gastroenterol; 2021 Nov; 56(11):951-963. PubMed ID: 34533632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.
    Younossi ZM; Noureddin M; Bernstein D; Kwo P; Russo M; Shiffman ML; Younes Z; Abdelmalek M
    Am J Gastroenterol; 2021 Feb; 116(2):254-262. PubMed ID: 33284184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
    Kuchay MS; Choudhary NS; Mishra SK; Misra A
    Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
    J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
    Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
    [No Abstract]   [Full Text] [Related]  

  • 15. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Spengler EK; Loomba R
    Mayo Clin Proc; 2015 Sep; 90(9):1233-46. PubMed ID: 26219858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies.
    Golabi P; Owrangi S; Younossi ZM
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S1-S9. PubMed ID: 38813821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
    Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review.
    Younossi ZM; Corey KE; Lim JK
    Gastroenterology; 2021 Feb; 160(3):912-918. PubMed ID: 33307021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.